Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Aclaris Therapeutics, Inc. stock logo
ACRS
Aclaris Therapeutics
$1.19
+1.7%
$1.22
$0.59
$11.12
$84.41M0.221.51 million shs1.63 million shs
Arcutis Biotherapeutics, Inc. stock logo
ARQT
Arcutis Biotherapeutics
$8.59
-1.8%
$10.17
$1.76
$15.21
$831.60M1.144.63 million shs2.25 million shs
Antibe Therapeutics Inc. stock logo
ATBPD
Antibe Therapeutics
$0.22
$0.39
$2.64
$3.50
$83.44M0.5729,710 shsN/A
Cassava Sciences, Inc. stock logo
SAVA
Cassava Sciences
$21.73
+4.8%
$21.50
$12.32
$32.10
$939.74M-0.45766,092 shs903,320 shs
7 Energy Stocks to Buy and Hold Forever Cover

Do you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Aclaris Therapeutics, Inc. stock logo
ACRS
Aclaris Therapeutics
-4.10%-4.88%+0.86%-6.40%-86.93%
Arcutis Biotherapeutics, Inc. stock logo
ARQT
Arcutis Biotherapeutics
+0.11%-14.63%-5.51%+80.79%-34.55%
Antibe Therapeutics Inc. stock logo
ATBPD
Antibe Therapeutics
0.00%0.00%-30.45%-68.62%-43.52%
Cassava Sciences, Inc. stock logo
SAVA
Cassava Sciences
+0.92%-2.49%+5.28%-15.62%+32.58%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Aclaris Therapeutics, Inc. stock logo
ACRS
Aclaris Therapeutics
1.7089 of 5 stars
3.11.00.00.02.61.71.3
Arcutis Biotherapeutics, Inc. stock logo
ARQT
Arcutis Biotherapeutics
1.092 of 5 stars
3.41.00.00.00.02.50.6
Antibe Therapeutics Inc. stock logo
ATBPD
Antibe Therapeutics
N/AN/AN/AN/AN/AN/AN/AN/A
Cassava Sciences, Inc. stock logo
SAVA
Cassava Sciences
3.3126 of 5 stars
3.50.00.04.71.80.80.6

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Aclaris Therapeutics, Inc. stock logo
ACRS
Aclaris Therapeutics
2.14
Hold$22.251,769.75% Upside
Arcutis Biotherapeutics, Inc. stock logo
ARQT
Arcutis Biotherapeutics
2.75
Moderate Buy$26.56209.15% Upside
Antibe Therapeutics Inc. stock logo
ATBPD
Antibe Therapeutics
N/AN/AN/AN/A
Cassava Sciences, Inc. stock logo
SAVA
Cassava Sciences
3.00
Buy$124.00470.64% Upside

Current Analyst Ratings

Latest ACRS, ATBPD, ARQT, and SAVA Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
4/12/2024
Arcutis Biotherapeutics, Inc. stock logo
ARQT
Arcutis Biotherapeutics
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$16.00
3/5/2024
Cassava Sciences, Inc. stock logo
SAVA
Cassava Sciences
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$124.00
2/28/2024
Arcutis Biotherapeutics, Inc. stock logo
ARQT
Arcutis Biotherapeutics
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetNeutral ➝ Neutral$6.00 ➝ $11.00
2/28/2024
Arcutis Biotherapeutics, Inc. stock logo
ARQT
Arcutis Biotherapeutics
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$8.00 ➝ $16.00
2/23/2024
Arcutis Biotherapeutics, Inc. stock logo
ARQT
Arcutis Biotherapeutics
Mizuho
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$8.00 ➝ $16.00
(Data available from 4/25/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Aclaris Therapeutics, Inc. stock logo
ACRS
Aclaris Therapeutics
$31.25M2.70N/AN/A$2.22 per share0.54
Arcutis Biotherapeutics, Inc. stock logo
ARQT
Arcutis Biotherapeutics
$59.61M13.95N/AN/A$0.94 per share9.14
Antibe Therapeutics Inc. stock logo
ATBPD
Antibe Therapeutics
$7.51M11.11N/AN/A$0.10 per share2.16
Cassava Sciences, Inc. stock logo
SAVA
Cassava Sciences
N/AN/AN/AN/A$3.26 per shareN/A

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Aclaris Therapeutics, Inc. stock logo
ACRS
Aclaris Therapeutics
-$88.48M-$1.27N/AN/AN/A-283.15%-64.56%-49.10%5/13/2024 (Estimated)
Arcutis Biotherapeutics, Inc. stock logo
ARQT
Arcutis Biotherapeutics
-$262.14M-$3.92N/AN/AN/A-439.79%-294.85%-78.57%5/14/2024 (Estimated)
Antibe Therapeutics Inc. stock logo
ATBPD
Antibe Therapeutics
-$14.54M-$0.60N/AN/AN/A-273.96%-150.49%-98.51%N/A
Cassava Sciences, Inc. stock logo
SAVA
Cassava Sciences
-$97.22M-$2.32N/A13.01N/AN/A-57.53%-52.58%5/6/2024 (Estimated)

Latest ACRS, ATBPD, ARQT, and SAVA Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
2/28/2024Q4 2023
Cassava Sciences, Inc. stock logo
SAVA
Cassava Sciences
-$0.40-$0.50-$0.10-$0.50N/AN/A
2/27/2024Q4 2023
Aclaris Therapeutics, Inc. stock logo
ACRS
Aclaris Therapeutics
-$0.37-$0.30+$0.07-$0.58$3.96 million$17.57 million
2/27/202412/31/2023
Arcutis Biotherapeutics, Inc. stock logo
ARQT
Arcutis Biotherapeutics
-$0.64-$0.72-$0.08-$0.72$11.78 million$13.53 million      

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Aclaris Therapeutics, Inc. stock logo
ACRS
Aclaris Therapeutics
N/AN/AN/AN/AN/A
Arcutis Biotherapeutics, Inc. stock logo
ARQT
Arcutis Biotherapeutics
N/AN/AN/AN/AN/A
Antibe Therapeutics Inc. stock logo
ATBPD
Antibe Therapeutics
N/AN/AN/AN/AN/A
Cassava Sciences, Inc. stock logo
SAVA
Cassava Sciences
N/AN/AN/AN/AN/A

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Aclaris Therapeutics, Inc. stock logo
ACRS
Aclaris Therapeutics
N/A
4.16
4.16
Arcutis Biotherapeutics, Inc. stock logo
ARQT
Arcutis Biotherapeutics
2.28
7.08
6.80
Antibe Therapeutics Inc. stock logo
ATBPD
Antibe Therapeutics
N/A
5.97
5.42
Cassava Sciences, Inc. stock logo
SAVA
Cassava Sciences
N/A
9.13
9.13

Ownership

Institutional Ownership

CompanyInstitutional Ownership
Aclaris Therapeutics, Inc. stock logo
ACRS
Aclaris Therapeutics
98.34%
Arcutis Biotherapeutics, Inc. stock logo
ARQT
Arcutis Biotherapeutics
N/A
Antibe Therapeutics Inc. stock logo
ATBPD
Antibe Therapeutics
N/A
Cassava Sciences, Inc. stock logo
SAVA
Cassava Sciences
38.05%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
Aclaris Therapeutics, Inc. stock logo
ACRS
Aclaris Therapeutics
8670.93 million67.02 millionOptionable
Arcutis Biotherapeutics, Inc. stock logo
ARQT
Arcutis Biotherapeutics
29696.81 million76.77 millionOptionable
Antibe Therapeutics Inc. stock logo
ATBPD
Antibe Therapeutics
47387.00 millionN/ANot Optionable
Cassava Sciences, Inc. stock logo
SAVA
Cassava Sciences
2943.25 million39.35 millionOptionable

ACRS, ATBPD, ARQT, and SAVA Headlines

SourceHeadline
Cassava Sciences (NASDAQ:SAVA)  Shares Down 6% Cassava Sciences (NASDAQ:SAVA) Shares Down 6%
americanbankingnews.com - April 21 at 5:34 AM
How Western food imports are fuelling obesity in Pacific nationsHow Western food imports are fuelling obesity in Pacific nations
msn.com - April 20 at 8:05 PM
Cassava Sciences, Inc. (SAVA)Cassava Sciences, Inc. (SAVA)
finance.yahoo.com - April 19 at 1:58 PM
Rail heralded as future for Thai logisticsRail heralded as future for Thai logistics
bangkokpost.com - April 17 at 1:27 PM
Cassava Sciences (NASDAQ:SAVA) Trading 6.2% Higher Cassava Sciences (NASDAQ:SAVA) Trading 6.2% Higher
marketbeat.com - April 16 at 3:43 PM
Cassava Sciences (NASDAQ:SAVA) Sees Large Volume IncreaseCassava Sciences (NASDAQ:SAVA) Sees Large Volume Increase
marketbeat.com - April 15 at 2:49 PM
Redemption Date Announced for WarrantsRedemption Date Announced for Warrants
globenewswire.com - April 15 at 9:20 AM
Contrasting Cassava Sciences (NASDAQ:SAVA) & Nabriva Therapeutics (NASDAQ:NBRV)Contrasting Cassava Sciences (NASDAQ:SAVA) & Nabriva Therapeutics (NASDAQ:NBRV)
americanbankingnews.com - April 15 at 1:44 AM
Nicklaus: Path to world food security goes through St. LouisNicklaus: Path to world food security goes through St. Louis
stltoday.com - April 14 at 7:17 AM
Cassava Sciences (NASDAQ:SAVA) Trading Down 9%Cassava Sciences (NASDAQ:SAVA) Trading Down 9%
marketbeat.com - April 12 at 2:51 PM
Vietnam has great potential for biofuel: expertsVietnam has great potential for biofuel: experts
vietnamnet.vn - April 12 at 2:00 PM
Investors Purchase Large Volume of Call Options on Cassava Sciences (NASDAQ:SAVA)Investors Purchase Large Volume of Call Options on Cassava Sciences (NASDAQ:SAVA)
marketbeat.com - April 11 at 4:50 PM
Cassava Sciences (NASDAQ:SAVA) Sees Strong Trading VolumeCassava Sciences (NASDAQ:SAVA) Sees Strong Trading Volume
marketbeat.com - April 9 at 3:19 PM
Fosukrom farmers trained on organic herbicides, pesticidesFosukrom farmers trained on organic herbicides, pesticides
modernghana.com - April 8 at 8:15 PM
Zambians Feel the Personal Consequences of Climate Change—and Dream of a Sustainable FutureZambians Feel the Personal Consequences of Climate Change—and Dream of a Sustainable Future
insideclimatenews.org - April 8 at 8:15 PM
Cassava Sciences (NASDAQ:SAVA) Trading Up 5.7%Cassava Sciences (NASDAQ:SAVA) Trading Up 5.7%
marketbeat.com - April 8 at 1:46 PM
Gates Foundation’s agtech arm sets up shop in St. Louis to help smallholders in AfricaGates Foundation’s agtech arm sets up shop in St. Louis to help smallholders in Africa
agfundernews.com - April 5 at 2:17 AM
5 Foods You Must Eat For A Longer, Healthier Life - Blue Zones Expert Reveals5 Foods You Must Eat For A Longer, Healthier Life - Blue Zones Expert Reveals
food.ndtv.com - April 5 at 1:13 AM
Ag nonprofit launched by Gates Foundation opens HQ in Cortex, grows to 30 employeesAg nonprofit launched by Gates Foundation opens HQ in Cortex, grows to 30 employees
bizjournals.com - April 5 at 1:13 AM
Strong quake rocks Taiwan, tsunami warnings issuedStrong quake rocks Taiwan, tsunami warnings issued
msn.com - April 4 at 4:16 PM
Can Africa one day help feed the world’s growing population?Can Africa one day help feed the world’s growing population?
ft.com - April 3 at 3:22 AM
Elevating knowledge about Africa in international business: KNUST’s Prof. Nathaniel Boso’s legacyElevating knowledge about Africa in international business: KNUST’s Prof. Nathaniel Boso’s legacy
myjoyonline.com - April 2 at 5:22 PM
24 HOUR DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Cassava24 HOUR DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Cassava
stockhouse.com - April 2 at 5:22 PM
Tracing science’s transformative impact on manifesto implementationTracing science’s transformative impact on manifesto implementation
msn.com - April 2 at 10:59 AM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

Aclaris Therapeutics logo

Aclaris Therapeutics

NASDAQ:ACRS
Aclaris Therapeutics, Inc. a clinical-stage biopharmaceutical company, engages in the development of novel drug candidates for immune-inflammatory diseases in the United States. The company operates through two segments, Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing therapies to address significant unmet needs for immuno-inflammatory diseases. The Contract Research segment provides laboratory services. It develops Zunsemetinib (ATI-450), an MK2 inhibitor which is under Phase 1b/2 trials for the treatment of metastatic breast and pancreatic cancer; ATI-1777, a soft JAK 1/3 inhibitor, completed Phase 2b trails for the treatment of moderate to severe atopic dermatitis and other dermatologic conditions; and ATI-2138, an oral covalent inhibitor of ITK and JAK3 inhibitor under Phase 1 trials as a treatment for T cell-mediated autoimmune diseases. The company was incorporated in 2012 and is headquartered in Wayne, Pennsylvania.
Arcutis Biotherapeutics logo

Arcutis Biotherapeutics

NASDAQ:ARQT
Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing ARQ-154, a topical ZORYVE for the treatment of scalp and body psoriasis and seborrheic dermatitis; ARQ-252, a selective topical janus kinase type 1 inhibitor for hand eczema and vitiligo; ARQ-255, a topical JAK1 inhibitor for alopecia areata; and ARQ-234, a CD200R fusion protein for the treatment of moderate-to-severe atopic dermatitis. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California.
Antibe Therapeutics logo

Antibe Therapeutics

OTCMKTS:ATBPD
Antibe Therapeutics Inc., a pharmaceutical development company, originates, develops, and out-licenses patent novel therapeutics and medical devices in the areas of pain, inflammation and regenerative medicine in Canada, Europe, the United States, and internationally. Its drugs are designed to prevent the gastrointestinal damage and bleeding caused by non-steroidal anti-inflammatory drugs. The company's lead compound is ATB-346, a hydrogen sulfide-releasing derivative of naproxen for treating rheumatoid arthritis, ankylosing spondylitis, and general pain reduction that has completed Phase 2B gastrointestinal safety study. Its products also comprise ATB-352, which is in preclinical stage for the treatment of gout, dental pain, post-surgical pain, etc.; and ATB-340 that is in preclinical development stage for the treatment of stroke and cancer. In addition, it offers bone graft substitutes, barrier membranes, and other products for the dental and orthopedic markets under the C-Graft Putty, C-Blast Putty, Eclipse, NeoGuarde, Neomem, Neomem FlexPlus, PentOS OI, and Raptos trademarks. The company was incorporated in 2009 and is headquartered in Toronto, Canada.
Cassava Sciences logo

Cassava Sciences

NASDAQ:SAVA
Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2 clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease. The company was formerly known as Pain Therapeutics, Inc. and changed its name to Cassava Sciences, Inc. in March 2019. Cassava Sciences, Inc. was incorporated in 1998 and is based in Austin, Texas.